Mutual of America Capital Management LLC Raises Holdings in PRA Health Sciences Inc (PRAH)

Mutual of America Capital Management LLC grew its position in PRA Health Sciences Inc (NASDAQ:PRAH) by 19.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 51,826 shares of the medical research company’s stock after buying an additional 8,327 shares during the quarter. Mutual of America Capital Management LLC owned 0.08% of PRA Health Sciences worth $5,711,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Carnegie Capital Asset Management LLC raised its position in shares of PRA Health Sciences by 0.9% in the 2nd quarter. Carnegie Capital Asset Management LLC now owns 59,966 shares of the medical research company’s stock worth $6,083,000 after acquiring an additional 556 shares in the last quarter. Strs Ohio raised its position in shares of PRA Health Sciences by 14.2% in the 3rd quarter. Strs Ohio now owns 4,582 shares of the medical research company’s stock worth $504,000 after acquiring an additional 569 shares in the last quarter. Bank of Montreal Can raised its position in shares of PRA Health Sciences by 12.8% in the 3rd quarter. Bank of Montreal Can now owns 6,491 shares of the medical research company’s stock worth $715,000 after acquiring an additional 738 shares in the last quarter. Twin Tree Management LP raised its position in shares of PRA Health Sciences by 59.7% in the 3rd quarter. Twin Tree Management LP now owns 2,058 shares of the medical research company’s stock worth $227,000 after acquiring an additional 769 shares in the last quarter. Finally, MML Investors Services LLC raised its position in shares of PRA Health Sciences by 34.7% in the 3rd quarter. MML Investors Services LLC now owns 3,006 shares of the medical research company’s stock worth $331,000 after acquiring an additional 774 shares in the last quarter. Institutional investors and hedge funds own 97.42% of the company’s stock.

Several research firms have recently commented on PRAH. BidaskClub lowered PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday. SunTrust Banks boosted their price target on PRA Health Sciences to $120.00 and gave the stock a “buy” rating in a research report on Monday, November 5th. UBS Group began coverage on PRA Health Sciences in a research report on Tuesday, October 9th. They issued a “neutral” rating for the company. Evercore ISI began coverage on PRA Health Sciences in a research report on Thursday, October 4th. They issued an “inline” rating and a $120.00 price target for the company. Finally, Robert W. Baird boosted their price target on PRA Health Sciences from $112.00 to $116.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 11th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $111.50.

Shares of NASDAQ:PRAH opened at $103.07 on Friday. PRA Health Sciences Inc has a 1 year low of $79.20 and a 1 year high of $121.98. The stock has a market cap of $6.91 billion, a P/E ratio of 28.21, a price-to-earnings-growth ratio of 1.54 and a beta of 0.77. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 1.22.

PRA Health Sciences (NASDAQ:PRAH) last announced its earnings results on Wednesday, October 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.07 by $0.06. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The company had revenue of $717.60 million for the quarter, compared to analyst estimates of $729.63 million. During the same period in the prior year, the company posted $0.88 EPS. The firm’s quarterly revenue was up 23.3% compared to the same quarter last year. Research analysts expect that PRA Health Sciences Inc will post 3.93 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.americanbankingnews.com/2018/12/08/mutual-of-america-capital-management-llc-raises-holdings-in-pra-health-sciences-inc-prah.html.

PRA Health Sciences Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Read More: Is a Roth IRA right for you?

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply